Lipum AB (publ) (LIPUM.ST)
SEK 13.3
(-1.48%)
SEK 13.3
(-1.48%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 12.11 Million SEK | -64.95% |
| 2022 | 34.55 Million SEK | -30.43% |
| 2021 | 49.66 Million SEK | 392.27% |
| 2020 | 10.08 Million SEK | -42.5% |
| 2019 | 17.54 Million SEK | 91.81% |
| 2018 | 9.14 Million SEK | 204.86% |
| 2017 | 3 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 66.14 Million SEK | 16.24% |
| 2024 Q2 | 56.89 Million SEK | 1531.72% |
| 2024 Q1 | 3.48 Million SEK | -71.21% |
| 2023 Q2 | 14.23 Million SEK | -49.64% |
| 2023 Q4 | 12.11 Million SEK | -35.53% |
| 2023 FY | 12.11 Million SEK | -64.95% |
| 2023 Q3 | 18.78 Million SEK | 31.94% |
| 2023 Q1 | 28.26 Million SEK | -18.18% |
| 2022 FY | 34.55 Million SEK | -30.43% |
| 2022 Q4 | 34.55 Million SEK | 175.35% |
| 2022 Q3 | 12.54 Million SEK | -45.22% |
| 2022 Q2 | 22.9 Million SEK | -26.15% |
| 2022 Q1 | 31.01 Million SEK | -37.55% |
| 2021 Q1 | 6.03 Million SEK | -40.17% |
| 2021 FY | 49.66 Million SEK | 392.27% |
| 2021 Q4 | 49.66 Million SEK | -20.5% |
| 2021 Q3 | 62.47 Million SEK | -11.76% |
| 2021 Q2 | 70.79 Million SEK | 1072.88% |
| 2020 Q3 | 15.13 Million SEK | 0.0% |
| 2020 FY | 10.08 Million SEK | -42.5% |
| 2020 Q4 | 10.08 Million SEK | -33.35% |
| 2019 FY | 17.54 Million SEK | 91.81% |
| 2018 FY | 9.14 Million SEK | 204.86% |
| 2017 FY | 3 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 89.776% |
| Ziccum AB (publ) | 14.97 Million SEK | 19.116% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | 39.574% |
| BioArctic AB (publ) | 1.18 Billion SEK | 98.979% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 80.586% |
| Mendus AB (publ) | 755.95 Million SEK | 98.398% |
| Genovis AB (publ.) | 288.85 Million SEK | 95.808% |
| Intervacc AB (publ) | 259.61 Million SEK | 95.335% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 71.138% |
| Active Biotech AB (publ) | 44 Million SEK | 72.477% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 95.656% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 80.516% |
| Aptahem AB (publ) | 63.02 Million SEK | 80.785% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 97.56% |
| Kancera AB (publ) | 65.64 Million SEK | 81.552% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 96.553% |
| Fluicell AB (publ) | 9.34 Million SEK | -29.657% |
| Saniona AB (publ) | 64.14 Million SEK | 81.12% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 63.96% |
| Biovica International AB (publ) | 131.4 Million SEK | 90.784% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 77.144% |
| AcouSort AB (publ) | 34.51 Million SEK | 64.912% |
| Xintela AB (publ) | 18.39 Million SEK | 34.167% |
| Abliva AB (publ) | 87.49 Million SEK | 86.16% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 98.407% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 99.038% |
| OncoZenge AB (publ) | 20.34 Million SEK | 40.462% |
| Amniotics AB (publ) | 26.08 Million SEK | 53.577% |
| 2cureX AB (publ) | 16.62 Million SEK | 27.158% |
| CombiGene AB (publ) | 120.61 Million SEK | 89.96% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -99.276% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 99.363% |
| Camurus AB (publ) | 1.9 Billion SEK | 99.365% |
| Corline Biomedical AB | 100.1 Million SEK | 87.903% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 93.163% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 91.387% |
| I-Tech AB | 152.44 Million SEK | 92.056% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 98.81% |
| Cyxone AB (publ) | 43.65 Million SEK | 72.26% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 84.611% |
| Biosergen AB | 7.2 Million SEK | -68.171% |
| Cantargia AB (publ) | 223.71 Million SEK | 94.587% |
| NextCell Pharma AB | 81.28 Million SEK | 85.102% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 98.418% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 59.865% |
| Nanologica AB (publ) | 77.42 Million SEK | 84.36% |
| SynAct Pharma AB | 228.01 Million SEK | 94.689% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | 54.751% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | 44.201% |
| LIDDS AB (publ) | 17.65 Million SEK | 31.408% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 99.135% |
| Alzinova AB (publ) | 123.18 Million SEK | 90.17% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 94.92% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -43.229% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 85.791% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | 18.555% |
| Simris Alg AB (publ) | 174.55 Million SEK | 93.062% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 94.42% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 98.147% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 86.092% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | 57.521% |